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Abstract High uniform fluid shear stress (FSS) is
atheroprotective and preserves the endothelial phenotype
and function through activation of downstream mediators
such as MAPK7 (Erk5). Endothelial cells respond to FSS
thanks to mechanotransduction. However, how the resulting
signaling is integrated and resolved at the epigenetic level
remains elusive. We hypothesized that Polycomb methyl-
transferase EZH2 is involved in the effects of FSS in human
endothelial cells. We showed that FSS decreases the expres-
sion of the Polycomb methyltransferase EZH2. Despite
simultaneous activation of MAPK7, MAPK7 pathway does
not directly influence the transcription of EZH2. Interestingly
though, the knockdown of EZH2 activates the protective
MAPK7 signaling in endothelial cells, even in the absence of
FSS. To understand the influence of the FSS-decreased
expression of EZH2 on endothelial transcriptome, we per-
formed RNA-seq and differential gene expression analysis.
We identified candidate groups of genes dependent on both
EZH2 and FSS. Among those, Gene Ontology overrepresen-
tation analysis revealed highly significant enrichment of the
cell cycle-related genes, suggesting changes in proliferation.
Indeed, the depletion of EZH2 strongly inhibited endothelial
proliferation, indicating cell cycle arrest. The concomitant
decrease in CCNA expression suggests the transition of
endothelial cells into a quiescent phenotype. Further bioin-
formatical analysis suggested TXNIP as a possible mediator
between EZH2 and cell cycle-related gene network. Our data
show that EZH2 is a FSS-responsive gene. Decreased EZH2
levels enhance the activation of the atheroprotective MAPK7
signaling.Decrease inEZH2under FSSmediates the decrease
in the expression of the network of cell cycle-related genes,
which allows the cells to enter quiescence. EZH2 is therefore
important for the protective effects of FSS in endothelium.
Keywords Endothelial cell  Enhancer of zeste homolog-
2 (EZH2)  Fluid shear stress (FSS) 
Mechanotransduction  Chromatin
Introduction
Endothelial cells constitute the lining of all blood vessels
and are therefore exposed to the fluid shear stress (FSS)—
the frictional force exerted on the vessel wall by the flow of
blood [1, 2]. Geometrical features of the arterial tree, such
as the aortic curve and branches, cause alterations in the
patterns of blood flow. At these so-called atheroprone sites,
FSS is low or even absent, which correlates with the
increased susceptibility of these sites to endothelial dys-
function and atherosclerosis [3–5].
Endothelial cells sense FSS through mechanotransduc-
tion. The FSS-induced activation of the MAP2K5–MAPK7
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(MEK5–Erk5) signaling pathway, which is sustained under
prolonged exposure to FSS [6], exerts protective effects on the
endothelium [7–9]. MEK5 activates MAPK7 through phos-
phorylation [8, 10], which results in expression of Kruppel-
like factor-2 and 4 (KLF2 and KLF4), transcription factors
that drive the expression of atheroprotective genes [8, 11].
Gene expression is regulated at the chromatin level
through the deposition or removal of epigenetic modifica-
tions by specialized enzymes. These modifications, to
histone proteins or to the DNA itself, shape the accessi-
bility of gene promoters to the transcriptional machinery.
In particular, Polycomb repressive complexes are crucial
regulators of gene expression, with well-established roles
during development and carcinogenesis [12]. Enhancer of
zeste homolog-2 (EZH2) is the main methyltransferase in
the Polycomb repressive complex-2 (PRC2). EZH2
methylates histone-3 at lysine-27 (H3K27me3 mark),
which maintains the repression of gene expression [13].
The epigenetic events that mediate cellular responses to
mechanical forces, such as the endothelial response to FSS,
are still poorly understood. EZH2 regulates the differenti-
ation of mechanosensing Merkel cells in the skin [14].
EZH2 was also shown to regulate endothelial gene
expression and function [15–17]. However, the link
between EZH2 and endothelial mechanotransduction in
response to FSS has not been reported.
We hypothesized that EZH2, through epigenetic regu-
lation of gene expression, mediates the response of
endothelial cells to the mechanical force of FSS.
Materials and methods
Cell culture and fluid shear stress experiments
Human umbilical vein endothelial cells (HUVEC; Lonza,
Basel, Switzerland) were used between passages 5 and 8,
cultured in endothelial cell medium (ECM) as described
before [18], but with 5.5 mM glucose and 10 % heat-in-
activated fetal calf serum (FCS; Lonza, Basel, Switzer-
land), in gelatin-coated dishes. For the FSS experiments, l-
Slides I 0.4 Luer (Ibidi, Planegg/Martinsried, Germany)
were coated with gelatin, and HUVEC were seeded at full
confluency (approximately 60,000 cells/cm2) and incu-
bated overnight under standard static cell culture condi-
tions. Slides with confluent cell monolayers were attached
to a fluidic unit (Ibidi, Planegg/Martinsried, Germany),
connected to the pump (Ibidi, Planegg/Martinsried, Ger-
many), and incubated under standard cell culture condi-
tions in 5 % FCS ECM. Inverted pressure was used to
ensure the gas exchange in the culture medium. Fluid shear
stress (FSS) of 20 dyne/cm2 was applied to the monolayers
in the slides, for 72 h. Static controls were cultured in the
same incubator and the same medium, refreshed daily. In
the stop-flow experiments, after FSS was ceased, cells were
incubated for an additional 1 h in static conditions before
they were lysed. MAP2K5–MAPK7 (MEK5–Erk5) path-
way inhibitor BIX02189 was used at the concentration of
5 lM. Simvastatin (Sigma-Aldrich, St. Louis, MO, USA)
was used at the concentration of 1 lM, for 24 h. Appro-
priate volumes of DMSO were used in controls.
Human embryonic kidney (HEK) cells and Phoenix-
Ampho cells were cultured in 10 % FCS DMEM (Lonza,
Basel, Switzerland), 2 mM L-glutamine (Lonza, Basel,
Switzerland), and 1 % penicillin/streptomycin (Gibco/
Thermo Fisher Scientific, Wiltham, MA, USA).
Viral transduction
In MEK5D expression experiments, Phoenix-Ampho cell
line stably expressing and producing retroviral particles
with empty vector (pBABE-puro-EV) or constitutively
active MEK5 (MAP2K5; pBABE-puro-MEK5D) was used.
Cells were cultured at subconfluent densities. The collection
of the viral particles was done in 10 % FCS ECM medium,
starting 24 h after the last preceding passage. The super-
natants were collected two times at 24 h intervals, filtered
through 0.45-lm filters and applied to 30 % confluent
HUVEC cultures. Twenty-four hours after the last trans-
duction medium was refreshed, and cells were cultured until
confluent. Upon selection with 2 lg/ml of puromycin (In-
vitrogen, Carlsbad, CA, USA), cells were allowed to pro-
liferate and then were lysed for further analysis.
For lentiviral transductions to obtain the EZH2 knock-
down,HEK cells were transfected usingEndofectinTM-Lenti
(Gene Copoeia, Rockville, MD, USA, EFL-1001-01) with
the following plasmids: pLKO.1-shEZH2 or pLKO.1-SCR,
pVSV-G (envelope plasmid) and pCMVDR8.91 (gag–pol
second generation packaging plasmid). Virus collection was
started the day after, in 10 % FCS ECM medium. At 24-h
intervals, 30 % confluent HUVEC were transduced twice.
Every first transduction was done with 4 lg/ml polybrene.
After the last transduction, cells were allowed to proliferate
for another 3 days and were then selected with 2 lg/ml of
puromycin. Surviving cells were allowed to proliferate for
another 24 h. At this point, 7 days post-first transduction,
cellswere used for downstream experiments or analyses. The
whole procedurewas repeated for each replicate. A complete
knockout of EZH2 (no protein present in western blotting
analyzes) was confirmed in all EZH2 knockdown cells used
in the experiments in this study.
siRNA transfection
HUVEC were seeded subconfluent and transfected at
80–90 % confluency, in 12-well plates. Cells were washed
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with PBS and pre-incubated with 400 ll of OptiMEM
(Invitrogen, Carlsbad, CA, USA) per well at 37 C.
Transfection mixes were prepared with lipofectamine (In-
vitrogen, Carlsbad, CA, USA) and siRNA against EZH2
(Hs_EZH2_4 FlexiTube siRNA, cat. no. SI00063973) or
AllStars Negative Control siRNA (cat. no. 1027280,
QIAGEN, Venlo, The Netherlands), and a 100 ll of an
appropriate mix containing 30 pmol of siRNA was added
per a well. Cells were incubated at 37 C for 6 h, then
washed two times with PBS, and cultured further in regular
culture medium. Medium was refreshed once more 48 h
post-transfection. Cells were lysed 72 h post-transfection.
RNA isolation and real-time PCR
Cells were lysed with either RNA-Bee (TEL-TEST, Inc.,
Friendswood, TX, USA) or TriZOL (Invitrogen, Carlsbad,
CA, USA). To isolate RNA, standard phenol/chloroform
extraction was performed in accordance with the manufac-
turer’s guidelines, followed by isopropanol precipitation.
RNA pellets were washed twice with ice-cold 75 % ethanol,
dried, and resuspended in RNAse-freewater. Concentrations
were measured by spectrophotometry (NanoDrop/Thermo
Fisher Scientific, Waltham, MA, USA). cDNA was synthe-
sized with the RevertAidTM First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific, Wiltham, MA, USA). Real-time
PCR (ViiA7 Real-Time PCR system, Applied Biosystems,
Foster City, CA, USA) was performed with 150 nmol of
primers and 10 ng of cDNA input per reaction, using SYBR
Green chemistry (BioRad, Hercules, CA, USA, or Roche,
Basel, Switzerland). Data were analyzed with the ViiA7
software (Applied Biosystems, Foster City, CA, USA) and
further processed in Excel. Geometrical mean of ACTB and
GAPDH Ct values, or only GAPDH Ct values (consistent
within an experimental set), was used for the DCt normal-
ization as follows: DCt ¼ CtGene of interest CtHousekeeping genes . Fold
change over control samples was calculated using DDCt
method, as 2DDCt , where DDCt ¼ DCtcontrol  DCttreatment .
Primers used in this study are shown in Table 1.
Western blotting
Cells were lysed with RIPA buffer (Thermo Fisher Sci-
entific, Wiltham, MA, USA), freshly supplemented with
proteinase inhibitor cocktail and phosphatase inhibitor
cocktails-2 and 3 (all from Sigma-Aldrich, St. Louis, MO,
USA). Electrophoresis was performed in 10 % polyacry-
lamide gels, followed by electrotransfer onto nitrocellulose
membranes. Membranes were blocked with Odyssey
Blocking Buffer (Li-COR Biosciences, Lincoln, NE, USA)
1:1 in Tris-buffered Saline (TBS) for 1 h at room tem-
perature (RT). Blots were then incubated with primary
antibodies at 4 C, overnight, and afterwards with sec-
ondary antibodies for 1 h at RT. The membranes were
washed three times with TBS with 0.1 % Tween in
between incubations and additionally with TBS before the
scanning. Odyssey scanner (Li-COR Biosciences, Lincoln,
NE, USA) was used to retrieve the digital images of the
membranes. These were analyzed with Odyssey software
(Li-COR Biosciences, Lincoln, NE, USA), and densitom-
etry was performed with TotalLab 120 software (Nonlinear
Dynamics, Newcastle, UK). Images depicted in fig-
ures were processed in Adobe Photoshop and Illustrator,
and if necessary, brightness of a whole image was adjusted
in linear fashion.
The following antibodies were used: NOS3/eNOS
(1:1000, BD Biosciences, San Jose, CA, USA, 610299),
MAPK7/Erk5 (1:500, Upstate/Merck Millipore, Billerica,
MA, USA, 07-039), EZH2 (1:1000, Cell Signaling,
Table 1 Primer sequences used in the study
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Danvers, MA, USA, 5246), GAPDH (1:1000, Abcam,
Cambridge, UK, ab9485 or ab9484), KLF2 (1:250, Santa
Cruz Biotechnology, Dallas, TX, USA, sc-28675), KLF4
(1:250, Santa Cruz Biotechnology, Dallas, TX, USA,
sc-20691), cyclin A (1:500, Santa Cruz Biotechnology,
Dallas, TX, USA, sc-751), cyclin B1 (1:500, Santa Cruz
Biotechnology, Dallas, TX, USA, sc-s45), cyclin E (1:500,
Santa Cruz Biotechnology, Dallas, TX, USA, sc-247), anti-
rabbit IgG IRDye-680LT (1:10 000, Li-COR Biosciences,
Lincoln, NE, USA, 926-68021), and anti-mouse IgG IRDye-
800CW (1:10 000, Li-COR Biosciences, Lincoln, NE, USA,
926-32210).
RNA-seq
Puromycin-selected HUVEC cells, expressing either scram-
bled control (SCR) or anti-EZH2 short-hairpin (shEZH2)
constructs (at total 7 days after the first viral transduction),
were used in FSS experiments (72 h of control static culture
or FSS exposure). Each replicate experiment consisted of
viral transductions (described above) and selection of a
separate HUVEC batch, followed by the FSS experiment.
Two FSS experimental sets of the same HUVEC batch were
run every time in parallel and lysed at the same end time
point, one in RNAse-free conditions with RNA-Easy Mini
Plus kit RLT Plus lysis buffer (QIAGEN, Venlo, The
Netherlands) and one with RIPA buffer. The RIPA lysates
were analyzed with western blotting and confirmed the
complete (no protein present) knockdown of EZH2.
From the RNA lysates, RNAwas isolated using the RNA-
Easy Mini Plus kit (QIAGEN, Venlo, the Netherlands).
High-quality RNA samples (pre-assessed by Nanodrop
measurements) were further processed in the Genome
Analysis Facility of the University Medical Center Gronin-
gen. The RNA quality and integrity were verified using
PerkinElmer Labchip GX with a cutoff value of 9 (scale
1–10, where 9 is very high-quality RNA). RNA library was
created in accordance with the TruSeqTM RNA Sample
Preparation v2Guide (Illumina, SanDiego, CA,USA), using
the PerkinElmer Sciclone liquid handler, resulting in 330-bp
cDNA fragments. The paired-end sequencing (100-bp reads)
was performed using the Illumina HiSeqTM 2500.
Sequencing data were analyzed using the Tuxedo pipeline
[19], with TopHat2 (v. 0.6), Cufflinks (v. 0.0.6), Cuffmerge
(v. 0.0.6), CuffDiff (v. 0.0.7), as available at the public
Galaxy platform usegalaxy.org as of August 2014 [20–22].
Prior to the alignment, FASTQ Groomer (v. 1.0.4) was used
to groom the .fq files, and FastQC (v. 0.52) was used to
assess the quality of the reads. Trim sequences tool (v. 1.0.0)
was used to trim the reads. Picard Insertion size metrics tool
(v. 1.56.0) was used to estimate the distance between mate
pairs (paired-end reads). Reads were aligned to the hg_19,
and iGenomes hg_19 (v. 1.1.3) was used for annotation.
Differential expression analysis was performed with
CuffDiff, with FPKM (Fragments Per Kilobase of exon per
Million fragments mapped) normalization method and
false discovery rate (FDR) correction, where corrected
p values (q values) \0.05 were considered to indicate
significant changes.
The CuffDiff output was explored using CummeRbund
(v. 0.1.3) in R-Studio 0.98. For the comparisons of interest,
the gene sets of significantly differentially expressed genes
were extracted at a = 0.05.
For a scheme of the subsequent analysis flow, please
refer to the Online Figure 5. Gene Ontology (GO) [23]
enrichment analysis was performed using the PANTHER
database, at the www.PANTHERdb.org Web site (PAN-
THER 9.0), as of August 2014 [24]. Gene lists were ana-
lyzed with the overrepresentation tool. The Bonferroni
correction for multiple testing was applied, and the cor-
rected p value (q value) of 0.05 was considered the cutoff
for significantly overrepresented terms.
The intersection of the lists of genes was performed with
the BioVenn tool [25]. The Venn diagrams were plotted
using the R package VennDiagram.
Pathway enrichment analysis was performed using
KEGG database using the Enrichr tools available at the
Enrichr Web site (with the combined ranking method) [26].
REVIGO online tool was used to organize and visualize
the enriched GO terms obtained from the PANTHER 9.0;
q values obtained in PANTHER GO enrichment analysis
were used as the rating parameter in REVIGO (only the
terms with q\ 0.05 were used) [27].
STRING 9.1 tool was used to explore the mutual rela-
tionships between the products of the genes [28, 29].
Additional information on the genes of interest, that can
be found in the online Tables, was retrieved from Ensembl
[30], using the BioMart tool [31].
The data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus [32] and




HUVEC expressing either scrambled control (SCR) or SH-
EZH2 constructs were seeded at density of 25,000 cells per
well in 24-well plates in 2 % FCS ECM and incubated for
24 h. After that cells were washed with PBS, fixed with
2 % paraformaldehyde for 30 min, washed with PBS,
permeabilized with 0.5 % Triton X in PBS for 10 min,
washed with PBS, and blocked with 10 % donkey serum in
PBS. Cells were then incubated with primary antibodies,
rabbit-anti-human Ki67 (1:500, Monosan, PSX1028) in
10 % donkey serum in PBS, while negative controls were
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incubated with the 10 % donkey serum in PBS, at 4 C
overnight. Cells were then washed with PBS with 0.05 %
Tween-20 and incubated with secondary antibodies, don-
key-anti-rabbit IgG Alexa Fluor-555 (1:500, Life Tech-
nologies, Carlsbad, CA, USA, A31572) in 10 % human
serum in PBS with DAPI (1:5000), for 40 min at RT. Cells
were next washed with PBS with 0.05 % Tween and with
PBS, the plates were scanned, and images were taken in an
automated manner with the Tissue FAXS microscope
(TissueGnostics, Vienna, Austria). Exposure of the images
was optimized and regulated by the software, and unpro-
cessed images were used in the quantitative analysis, per-
formed with the Tissue Quest 4.0.1.0127 software
(TissueGnostics, Vienna, Austria), which counts the posi-
tive cells and measures the fluorescence intensity. The data
were normalized by dividing the Ki67-positive cell num-
bers by all DAPI-positive cell numbers. The brightness of
the representative images depicted in Fig. 7 was adjusted in
a linear manner and to the same extent in each image, to
better visualize the stained cells.
Statistical analysis
Statistical analysis was performed in GraphPad Prism 4 or
5 (La Jolla, CA, USA), with t test, or one-way ANOVA
followed by post hoc tests with corrections specified in
figure legends. Graphs depict mean and standard deviation
or SE of the mean (specified in figure legends), and the
number of independent experiments is indicated in the dot
plots and in figure legends. p values\0.05 were considered
to indicate a significant difference between means.
Results
Fluid shear stress regulates EZH2 expression
in endothelial cells
FSS of 20 dyne/cm2 decreased the expression of EZH2 in
HUVEC (Fig. 1a–c). As expected, it also activated
MAPK7 signaling (Fig. 1a) and increased expression of
KLF2, KLF4, and endothelial nitric oxide synthase (NOS3/
eNOS) (Online Fig. 1 A–F).
To evaluate whether the decrease in EZH2 expression
under FSS is a result of MAPK7 activation, we expressed
MEK5D, a constitutively active mutant of MEK5/MAP2K5
[8], in endothelial cells. MEK5D expression resulted in
activation of MAPK7 (Fig. 2a) and increased the expression
of KLF2 and KLF4 (Online Fig. 2A and B), confirming that
the model worked properly. MAPK7 activation coincided
with decreased expression of EZH2 at the protein level, but
not at the mRNA level (Fig. 2a–c). Pharmacological
Fig. 1 FSS causes a decrease in EZH2 gene and protein expression.
HUVEC were cultured for 72 h under 20 dyne/cm2 FSS. a Represen-
tative western blotting images. b Gene expression of EZH2 under
FSS, n = 4, **p\ 0.01, t test and c protein expression of EZH2
under FSS, obtained through the densitometry of the western blotting
data, n = 3, **p\ 0.01, t test
Fig. 2 Protein expression of EZH2 is decreased along MAPK7
activation. The constitutively active MEK5 mutein (MEK5D) was
expressed in HUVEC. a Representative western blotting images.
b Protein expression of EZH2 in cells expressing MEK5D, obtained
through the densitometry of the western blotting data, n = 6,
*p\ 0.05, t test and c gene expression of EZH2 in cells expressing
MEK5D, n = 4
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inhibition of MAPK7 activation by the small molecule
inhibitor BIX02189 did not rescue the expression of EZH2
decreased by FSS (Online Fig. 3A) or by treatment with
simvastatin (Online Fig. 3B). These data suggested that
while FSS decreases the expression of EZH2 in HUVEC,
MAPK7 is not involved in mediating this effect.
Depletion of EZH2 enhances MAPK7 activation
Although it did not directly regulate the expression of
EZH2, MAPK7 is an important mediator of FSS in
endothelial cells. We therefore investigated how, on the
other hand, the FSS-induced decrease in EZH2 affects the
expression and activity of MAPK7. Knockdown of EZH2
by either shRNA or siRNA did not alter the gene expres-
sion levels of MAPK7 in endothelial cells (Fig. 3a and
Online Fig. 4A and B). However, knockdown of EZH2 did
increase the basal phosphorylation levels of MAPK7 under
static conditions (Fig. 3b, c) as well as enhanced the acti-
vation of MAPK7 in the cells exposed to FSS (Fig. 3d–g).
These data imply that the levels of EZH2 determine the
activation capacity of MAPK7 in endothelial cells. As
MAPK7 activation is maintained upon prolonged exposure
to FSS [6], we checked whether the decrease in EZH2
expression under FSS would modulate the deactivation
(dephosphorylation) of MAPK7 after FSS was stopped.
The decrease in EZH2 under FSS (Fig. 3h, i) did not affect
the dephosphorylation of MAPK7 within 1 h after the FSS
exposure was stopped, as the MAPK7 phosphorylation
levels were diminished to a level comparable with static
control samples. These data suggest that MAPK7 activa-
tion, rather than deactivation, is affected by the decrease in
EZH2 (Fig. 3h, j, ‘‘1-h stop FSS’’/‘‘stop’’).
EZH2 regulates genes involved in cell adhesion
and cell cycle in endothelial cells
To understand the role of EZH2 in the regulation of tran-
scription in endothelial cells in response to FSS, we
employed a transcriptomic approach (Online Fig. 5). First,
the genes regulated by the knockdown of EZH2 or by FSS
were explored separately, to gain insight into the groups of
genes affected by either condition. Then, the groups of
genes regulated by both EZH2 depletion and FSS exposure
were identified. In both cases, Gene Ontology overrepre-
sentation analysis was performed to classify the differen-
tially expressed genes and to identify the most significantly
enriched groups of genes (which are likely to be highly
biologically relevant in the conditions tested). Overview of
the analysis is presented in Online Fig. 5.
RNA-seq analysis of control (SCR) and EZH2-depleted
(SH-EZH2) cells showed that the depletion of EZH2 in
endothelial cells increased the expression of 2042 genes
(q\ 0.05), of which 550 were increased Ctwofold (Online
Table 1). Overrepresentation analysis of these genes using
PANTHER database revealed that the most significantly
overrepresented biological process (BP) Gene Ontology
(GO) term was cell adhesion (Fig. 4a upper panel and
Online Table 2), with 58 genes (Online Fig. 6A). Of 2654
genes whose expression was decreased in cells depleted of
EZH2 (q\ 0.05), 760 genes were Ctwofold decreased
(Online Table 1). The most overrepresented group within
these 760 genes was the genes associated with the BP GO
term cell cycle (Fig. 4a lower panel, and Online Table 3),
including 136 genes (Online Fig. 6B).
FSS-regulated genes in endothelial cells
Next, we analyzed the transcriptomic effects of FSS in
endothelial cells. Exposure of endothelial cells to FSS
increased the expression of 2142 genes (q\ 0.05) of which
615 genes were increased Ctwofold (Online Table 4), with
the most significantly overrepresented groups within the
BP GO terms cellular process, developmental process, and
cell adhesion (Fig. 4b upper panel, Online Fig. 7A and
Online Table 5). FSS decreased the expression of 3035
cFig. 3 EZH2 levels determine the activation capacity of MAPK7.
a Gene expression of MAPK7 in cells depleted of EZH2. Anti-EZH2
shRNA was expressed in HUVEC for 7 days by means of lentiviral
delivery. Scrambled shRNA was used as control, n = 3. b Represen-
tative images of western blotting showing the enhanced activation of
MAPK7 in static conditions upon 7-day knockdown of EZH2 in
HUVEC. c Densitometry results showing the enhanced activation of
MAPK7 in static conditions upon the knockdown of EZH2, derived
from the western blotting data, normalized to b-actin (ACTB), n = 3,
**p\ 0.01, t test. d Representative western blotting images, showing
enhanced activation of MAPK7 in EZH2-depleted cells compared to
control, both in static and in FSS-exposed cultures. Dashed line
indicates where the images were artificially connected: they are parts
of the same membrane (one image) and were only moved to depict the
lanes in the order which is easier for interpretation. Control and
EZH2-depleted HUVEC were cultured under FSS for 3 days.
e Densitometry results of the western blotting data showing the
protein expression levels of EZH2, n = 3, **p\ 0.01, ***p\ 0.001,
one-way ANOVA with Tukey’s post hoc comparisons between all
pairs of means. f, g Densitometry results of the western blotting data
showing the total phosphorylation levels of MAPK7 (normalized to
GAPDH) and the ratio of phosphorylated MAPK7 to total expressed
MAPK7 (both normalized to GAPDH), respectively, n = 3,
**p\ 0.01, ***p\ 0.001, one-way ANOVA with Tukey’s post
hoc comparisons between all pairs of means. h Representative
western blotting images showing rapid dephosphorylation of MAPK7
upon the cessation of the flow. Cells were cultured for 72 h in static
conditions or under FSS; afterwards one group was kept for an
additional 1 h in static conditions before cells lysis (‘‘1-h stop FSS’’)
and i, j Densitometry results showing the levels of MAPK7
phosphorylation and EZH2 protein expression, respectively, normal-
ized to GAPDH. The ‘‘stop’’ caption refers to the 1-h stop FSS
condition (see h), n = 3, ***p\ 0.001, one-way ANOVA with
Tukey’s post hoc comparisons between all pairs of means
14 Angiogenesis (2016) 19:9–24
123
Angiogenesis (2016) 19:9–24 15
123
genes (q\ 0.05), of which 835 genes were Ctwofold
decreased (Online Table 4). The most enriched group was
associated with the BP GO term cell cycle (Fig. 4b lower
panel, Online Fig. 7B and Online Table 6).
Identification of candidate genes regulated by EZH2
in response to FSS in endothelial cells
We next set out to identify the genes that are affected by
both EZH2 and FSS, which are the candidate genes regu-
lated by the decrease in EZH2 under FSS. The expression
of 103 genes increased, and the expression of 355 genes
decreased upon both the depletion of EZH2 and the
exposure to FSS (Fig. 5a, b, and Online Tables 7 and 8).
The group of 103 genes with increased expression was
the most significantly enriched in genes belonging to the BP
GO term cell adhesion (Fig. 5c and Online Table 9). The
group of 355 genes with decreased expression was the most
significantly enriched in genes associated with the BP GO
term cell cycle (Fig. 5d, right panel and Online Table 10).
Additional pathway enrichment analysis with Enrichr
using KEGG database showed significant enrichment of
terms cell adhesion molecules (genes with increased
expression, Online Fig. 8A) and cell cycle (genes with
decreased expression, Online Fig. 8B).
The FSS-exerted decrease in EZH2 inhibits
endothelial proliferation through downregulation
of cell cycle-associated network of genes
The expression of genes associated with the term cell
adhesion, increased by the depletion of EZH2 and exposure
Fig. 4 Biological process Gene Ontology terms which were signif-
icantly overrepresented among genes regulated by EZH2 (panel a) or
by FSS (panel b). The figure shows the REVIGO representation of
GO BP terms enriched in the lists of genes regulated twofold or more
upon EZH2 depletion (a) or FSS exposure (b). The lists of GO
significantly enriched terms (cutoff q\ 0.05) were obtained through
the overrepresentation analysis using PANTHER 9.0. The size of a
bubble corresponds to the size of the group of genes in the analysis,
belonging to the specific GO term. UP upregulated genes, DOWN
downregulated genes. For the exact (corrected) p values, please
compare Supplementary Tables 2, 3, 5 and 6
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to FSS, was in most cases also increased in the EZH2-
depleted cells under FSS (Online Fig. 9A). However, most
of these genes have not been reported to interact with each
other (Online Fig. 9B), as they did not seem to form a
functional network based on String 9.1 analysis. We
therefore continued with the analysis of the Cell cycle-
associated genes.
The expression of genes associated with the GO term
cell cycle was decreased/suppressed by EZH2 depletion, by
FSS exposure, and in EZH2-depleted cells under FSS
(Fig. 6a). Real-time PCR validation of a subset of these
genes confirmed this expression pattern (Fig. 6b). It further
confirmed that the expression of master regulators of cell
cycle progression such as CCNA2, CCNB1, or CCNB2 [33]
was decreased by both FSS and the depletion of EZH2 in
endothelial cells (Fig. 6b).
Most of the products of the cell cycle-related genes we
identified (Fig. 6a) were interconnected by mutual rela-
tionships (Fig. 7a). These results suggested that the
decrease in expression of these cell cycle-related genes
could be a part of an orchestrated response, regulated by
FSS through the decrease in EZH2, and aimed at the
inhibition of cell cycle progression and proliferation.
To confirm that low levels of EZH2 functionally inhibit
the cell cycle, we demonstrated that the depletion of EZH2
indeed decreased the proliferation rates of endothelial cells
(Fig. 7b, c). These data suggested that the decrease in
EZH2 (under FSS) could lead to the cell cycle arrest.
Fig. 5 Genes regulated by both EZH2 and FSS are the most
significantly enriched within GO terms cell adhesion and cell cycle.
a Area-proportional Venn diagram, depicting the intersection of the
lists of genes upregulated by EZH2 depletion (SCR-static vs. SH-
EZH2-static) and genes upregulated by exposure to FSS (SCR-static
vs. SCR-FSS). b Area-proportional Venn diagram, depicting the
intersection of the lists of genes downregulated by EZH2 depletion
(SCR-static vs. SH-EZH2-static) and genes downregulated by expo-
sure to FSS (SCR-static vs. SCR-FSS). c REVIGO-derived
representation of the most significantly overrepresented GO BP terms
in the list of 103 genes upregulated by both EZH2 depletion and FSS
exposure and d REVIGO-derived representation of the most signif-
icantly overrepresented GO BP terms in the list of 355 genes
downregulated by both EZH2 depletion and FSS exposure. The
significantly enriched GO terms (q\ 0.05) were derived from the
PANTHER 9.0 overrepresentation analysis. The GO enrichment
q values are available in Supplementary Tables 9 and 10
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To further validate this notion, we analyzed the protein
expression of chosen cyclins whose expression was
decreased in our transcriptomic data. While cyclin B
(CCNB) and cyclin E (CCNE) did not show consistent
changes in protein expression, cyclin A (CCNA) protein
levels were decreased both by the depletion of EZH2 and
by the exposure to FSS (Fig. 7d, e). These patterns of
expression, in particular the decrease in cyclin A levels,
seemed to be specifically dependent on EZH2 and inde-
pendent from the MEK5/MAPK7 pathway, as they were
not observed in MEK5D-expressing cells (Fig. 7d, e).
As EZH2 is an epigenetic repressor, there could be other
gene products, likely repressors, which are upregulated and
mediate between the decrease in EZH2 availability and the
decrease in cell cycle-related gene expression. To explore
this possibility, we performed an additional GO overrep-
resentation analysis of all the genes regulated by EZH2
depletion and FSS exposure (up- and downregulated genes
together). As could be expected, the GO term cell cycle
was once more the most significantly overrepresented. In
addition to the downregulated genes identified before
(Fig. 6a), this analysis revealed five cell cycle-related
genes, MAPK13, TRNP1, TUBA4A, GEM, and TXNIP,
whose expression was increased in EZH2-depleted and in
FSS-exposed cells (Fig. 7f). This small group of genes
provides a set of potential mediators between EZH2 and
the downregulated cell cycle-regulating genes.
Discussion
We demonstrated that EZH2 is a fluid shear stress (FSS)-
responsive gene. EZH2 levels influence the activation
levels of MAPK7. EZH2 regulates the expression of mul-
tiple groups of genes in endothelial cells. In particular, it
regulates the genes associated with cell adhesion and cell
cycle. The FSS-induced decrease in EZH2 levels elicits an
orchestrated response of cell cycle-regulating genes, which
leads to inhibition of endothelial cell proliferation and
likely to quiescence.
Our data altogether suggest that high FSS might keep the
EZH2 expression levels low, which preserves the protected,
quiescent state of endothelium. On the other hand, in case of
low or absent FSS, e.g., in atheroprone arterial regions, high
expression of EZH2 could contribute to endothelial dys-
function, e.g., by releasing endothelial cells from quiescence
and promoting their (excessive) proliferation.
We demonstrated that high FSS is able to decrease the
expression of the global epigenetic regulator, EZH2, at
both mRNA and protein level. This decrease in expression
of EZH2 seems to mediate some of the beneficial effects of
FSS. Our RNA-seq analysis identified groups of genes
dependent both on the EZH2 levels and on the presence of
FSS. It is not surprising that there are several groups of
genes (as classified by Gene Ontology terms) that are
affected: on one hand, FSS is an important factor regulat-
ing many aspects of endothelial cell biology, and on the
other hand EZH2 is a global epigenetic regulator, acting on
multiple genomic loci. In the current study, we focused on
the most significantly enriched group of cell cycle-related
genes. However, exploration of the other groups of genes
identified in this study could provide further examples of
singular pathways regulated by FSS through decrease in
EZH2.
The mechanism of the regulation of EZH2 expression by
FSS remains to be fully elucidated. However, we suc-
ceeded in demonstrating that the major known FSS-in-
duced pathway, MEK5/MAPK7 pathway, is of minor
importance for regulation of EZH2 expression. Other
pathways should be assessed in future studies. Further-
more, we established an exciting novel feedback link
between EZH2 and MAPK7 pathway, by showing that
MAPK7 activation capacity is increased when EZH2 levels
decrease. This means that the protective, long-term acti-
vation of MAPK7 by high FSS could be mediated by the
FSS-induced decrease in EZH2 levels.
A few other studies that so far reported on the role of
EZH2 in endothelial cells confirm that EZH2 is involved in
the regulation of endothelial gene expression and
endothelial function [15, 16]. In particular, EZH2 regulates
angiogenesis in the tumor microenvironment, where it is
itself regulated by VEGF-miRNA-101 axis [16, 17, 34].
One study has so far addressed the role of EZH2 in
endothelial cells with a global approach, similar to ours,
but in static conditions only. Dreger et al. [15] studied the
short-term effects of a transient (siRNA-mediated) knock-
down of EZH2 in HUVEC. They reported enrichment of
cell communication and cell adhesion-related genes among
the genes regulated by EZH2, which corroborates our
finding that the cell adhesion genes are the most enriched
group among the genes upregulated by the knockdown of
EZH2. The main difference between the studies is that we
used a stable and long-term knockdown of EZH2 (total
knockdown time of 10 days). Our approach allowed us to
study more downstream (and secondary) effects of EZH2
depletion, which correspond well to the effects of the
continuously low EZH2 levels under prolonged exposure to
bFig. 6 Cell cycle-associated genes are a candidate group of genes
regulated by the decrease in EZH2 upon FSS. a Heatmap represen-
tation of relative expression levels of genes associated with the BP
GO term cell cycle, which were regulated by both EZH2 depletion
and FSS exposure and b Real-time PCR validation of the RNA-seq
results for a subgroup of the cell cycle-associated genes, n = 3, error
bars depict SE of the mean, **p\ 0.01, ***p\ 0.001 one-way
ANOVA with Tukey’s post hoc comparisons between all pairs of
means
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FSS. These long-standing effects are more similar, and
likely more relevant, to the conditions of continuous blood
flow and FSS in the blood vessels.
Therefore, our results extend the current knowledge on
the role of EZH2 in endothelial cells, investigated so far
only in static conditions, by providing insights into the role
of EZH2 under mechanical force of FSS.
FSS also affects some of the other epigenetic regulators,
such as histone deacetylases (HDACs) [35–37] and miR-
NAs [37, 38]. Moreover, recent studies demonstrated the
role of DNA methylation in mediating the effects of FSS in
endothelium, further substantiating the importance of epi-
genetic mechanisms in mediating the mechanosignaling
[39, 40]. Our study is the first to add Polycomb and the
histone methyltransferase EZH2 to the group of epigenetic-
level regulators of endothelial response to FSS.
The genes related to GO term cell cycle were the most
significantly enriched group regulated by the decrease in
EZH2 and by FSS in our study. These genes form a dense
network of interactions, suggesting that their products
function together to regulate cell cycle progression. Indeed,
for example, CDK1 is a major cell cycle regulator, which at
different stages binds CCNA1 [41], CCNA2 [42], CCNB1
[43], and CCNB2 [44], and all of these genes were
downregulated by EZH2 depletion and by FSS in our
experiments. CDK1 also links directly to EZH2, as it can
bind and phosphorylate EZH2 to change its epigenetic
activity [45, 46]. The presence of these and many other
concomitant interactions between the members of this
group suggests that it is indeed a functional network, whose
orchestrated downregulation serves to inhibit the cell cycle
progression in endothelial cells. Indeed, our results show
that depletion of EZH2 caused decrease in proliferation of
endothelial cell, while others observed that high expression
of EZH2 promotes the proliferation of many types of
cancer cells [47–50]. These data imply that the decrease in
EZH2 under FSS likely serves as the mechanism to
downregulate the network of cell cycle regulators, there-
fore inhibiting the proliferation of endothelial cells.
EZH2 is an epigenetic repressor, which suggests that the
decrease in EZH2 expression is more likely to induce
expression of genes, rather than to decrease it. However,
other groups investigating the transcriptomic effects of
EZH2 also found that its inhibition or knockdown results in
both increase and decrease in expression of genes, which is
consistent with our findings [51, 52]. Nevertheless, we
attempted to identify a possible link between the cell cycle-
related genes and EZH2 in our study, by looking for an
upregulated EZH2-dependent and cell cycle-related gene.
The additional GO overrepresentation analysis revealed
five cell cycle-related genes, MAPK13, TRNP1, TUBA4A,
GEM, and TXNIP, which were upregulated by both EZH2
depletion and FSS exposure.
Of those candidate genes, TXNIP is the only one so far
reported to be affected by EZH2. In the study by Zhou
et al. [51], TXNIP expression was increased by EZH2
inhibition, which resulted in suppression of cell growth.
These data are therefore consistent with our findings of
TXNIP expression being upregulated and endothelial pro-
liferation being inhibited in EZH2-depleted cells.
TXNIP (thioredoxin interacting protein, also known as
VDUP1) is primarily related to oxidative stress regulation.
However, it has been recognized as a tumor suppressor
gene whose upregulation inhibits the growth of cancer cells
[51, 53, 54]. This inhibitory effect of TXNIP has been
linked to the cell cycle arrest in G1/G0 phase [53, 55].
Therefore, TXNIP is a likely mediator of the cell cycle
arrest occurring after the decrease in EZH2 under FSS.
This could happen through the known TXNIP-depen-
dent stabilization of p27 (CDKN1B) protein, which is a
negative regulator of cell cycle [53, 54]. CDKN1B
expression was indeed shown to be reversely correlated
with EZH2 levels [56, 57]. Our results reproduced such
increase in CDKN1B levels upon EZH2 depletion (Online
Table 1). However, the CDKN1B expression was not
affected by FSS in our dataset, suggesting that CDKN1B is
not involved in FSS-induced inhibition of cell cycle.
Another potential target gene downstream of TXNIP is
CCNA (cyclin A). The study by Han et al. [55] showed that
TXNIP can act as a transcriptional repressor and is able to
repress the promoter activity of CCNA2. CCNA expression
was decreased in our experiments both at gene and protein
level. Therefore, the EZH2-TXNIP-CCNA2 axis provides
bFig. 7 Downregulation of the network of cell cycle-associated genes
leads to the decrease in proliferation of endothelial cells. a Products
of the genes associated with the GO term cell cycle, which are
regulated by both EZH2 and FSS, form a network of interdependen-
cies. The list of genes regulated by both EZH2 and FSS belonging to
the GO term cell cycle (most significantly enriched group) was
analyzed using String 9.1. Depicted is the evidence view of
interactions between the gene products. b Representative images of
the immunofluorescent staining detecting the Ki67 protein expression
in scrambled control (SCR) and EZH-depleted (SH-EZH2) endothe-
lial cells (upper panel). Lower panel depicts DAPI signal, indicating
nuclear staining. The white bars indicate 100 lm. c The average
percentage of proliferating cells, derived as the percentage of Ki67-
positive cells among all the DAPI-positive cells [i.e., Ki67-positive
cell numbers are normalized to the number of all cells (DAPI) in the
quantified region], showing the decrease in proliferation capacity of
the EZH2-depleted cells. These results were obtained through the
analysis with the TissueFAXS TissueQuest software, n = 4,
***p\ 0.001, t test. d Representative western blotting results of
protein expression of cyclins A, B and E. e Densitometric quantifi-
cation of the protein expression of cyclins A, B and E, normalized to
GAPDH. n = 4, *p\ 0.05, **p\ 0.01, Student t test, error bars
depict SE of the mean and f Heatmap representation of the relative
expression of MAPK13, TRNP1, TUBA4A, GEM, and TXNIP, the
cell cycle-related genes whose expression was increased by both
EZH2 depletion and FSS exposure in HUVEC
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an interesting example of a link between EZH2 and cell
cycle regulation. Nevertheless, it might be one of multiple
connections feeding into the reported network of genes,
while the whole network is important for the net effect of
cell cycle inhibition.
The decrease in expression of EZH2 under FSS, along
with the decrease in expression of cell cycle-regulating
machinery, results in the decrease in proliferation, suggest-
ing that the endothelial cells enter quiescence—the arrest of
the cell cycle in G1/G0 phase. Endothelial cells are known
to acquire a quiescent phenotype under high FSS [1, 11, 58].
Quiescence was also observed upon inhibition of EZH2 in
multiple cell lines [59, 60]. In B lymphocytes, the decrease
in EZH2 levels was necessary for entering the quiescent
state [61]. Interestingly, both the increase in TXNIP and the
decrease in cyclin A levels, consistently with our findings,
have also been associated with G1/G0 arrest, and hence the
quiescent phenotype [53, 55, 60, 62].
The quiescent state of endothelium under high FSS is
deemed beneficial and protective for endothelium.
Endothelial cells in the regions of disturbed flow proliferate
intensively, which might result in their early senescence
and contribute to the susceptibility of such vascular foci to
atherosclerotic remodeling [1, 58]. We showed that the
decrease in EZH2 levels also enhances the activation of
MAPK7, a major FSS-responsive MAP kinase, which
promotes atheroprotection through increased expression of
KLF2, KLF4, and NOS3 [7–9, 63, 64]. Altogether, our
results indicate that the suppression of EZH2 expression by
high FSS is one of the mechanisms mediating the beneficial
effects of high FSS in endothelial cells.
Our data establish EZH2 as a regulator of endothelial
gene expression, involved in the endothelial response to
FSS. In particular, we propose that the suppression of
EZH2 expression by high FSS restricts the expression of a
whole network of cell cycle-regulating genes, which results
in the protected quiescent endothelial phenotype (Fig. 8).
Given the atheroprotective role of high FSS and the
availability of several EZH2 inhibitors, our results further
suggest that EZH2 might become a promising pharmaco-
logical target to treat or prevent vascular disease.
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